A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

(2010) G. Dasmahapatra et al.   BLOOD

Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents

(2010) L A Moulopoulos et al.   LEUKEMIA

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

(2009) F. Parlati et al.   BLOOD

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

(2009) A. Badros et al.   CLINICAL CANCER RESEARCH

PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF- B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells

(2009) S. Bhalla et al.   CLINICAL CANCER RESEARCH

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)

(2009) Han-Jie Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells

(2008) Y. Dai et al.   CLINICAL CANCER RESEARCH

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma

(2007) M. Chatterjee et al.   BLOOD